Arcus is at the forefront of designing combination therapies, with best-in-class potential, in our relentless pursuit of cures for cancer.
Founded in 2015, Arcus Biosciences is a highly productive, clinical-stage, global biopharmaceutical company with the goal of developing best-in-class molecules and combination therapies for people with cancer. Our team of scientists, physicians, advisors and other leaders is focused on targeting well-understood biological targets and pathways where there is an opportunity to develop new medicines with a potentially improved safety and efficacy profile.
One of Arcus’s key competitive advantages is a highly productive, industry-leading team of individuals that runs our world-class discovery engine and development organization. We believe that discovery is not a commodity, and we have invested in building exceptional small molecule, medicinal chemistry and antibody capabilities to optimize the combinability of molecules within our portfolio.
Through thoughtful partnerships with industry partners, patients and physicians, Arcus aims to accelerate the development and delivery of new treatments. Our development process is guided by specific biologic mechanisms of cancer, enabling rapid progression from Phase 1 studies to commercialization, with the ultimate goal of bringing life-changing therapies to patients faster.
